Medigen applies for Australian vaccine approvalBy Kao Shih-ching / Staff reporterMedigen Vaccine Biologics Corp (高端疫苗) has applied to the Australian medicines regulator for provisional approval of its COVID-19 vaccine, the pharmaceutical company said in a filing with the Taipei Exchange yesterday. The TGA in November last year gave the Medigen vaccine a provisional determination, the first step to provisional approval, corporate data showed. Vials of Medigen Vaccine Biologics Corp’s MVC COVID-19 vaccine are pictured in Taipei on Feb. 8. Medigen reported a net loss of NT$140 million (US$4.76 million) in the first quarter, or losses per share of NT$0.66. The company’s operating expenses grew 27.5 percent annually to NT$361 million last quarter due to higher marketing and research spending, company data showed.
